Dr Joyce Ohm explains how sequencing tumor genomes reveals the mutations needed to design targeted cell and gene therapies for cancer patients. In part 2 of this interview, Joyce Ohm, PhD, explains ...

Dr. Monty Pal begins the discussion on treatment sequencing in advanced renal cell carcinoma (RCC) by emphasizing the ...

Dr. Monty Pal discusses his approach to selecting second-line therapy for advanced renal cell carcinoma (RCC) based on the ...

Dr. Ticiana Leal from Emory University's Winship Cancer Institute and Dr. Wade Iams from Tennessee Oncology introduce their discussion on Lambert-Eaton myasthenic syndrome (LEMS) in patients with ...

Peers & Perspectives® in Oncology delivers exclusive coverage of virtual and in-person live events held by Targeted Oncology and Healthcare Research & Analytics®, thought leader collaborations, and ...

Immunosuppression confers markedly elevated cSCC risk, with transplant recipients experiencing 65- to 100-fold higher ...

FDA accepted an NDA for daraxonrasib in previously treated metastatic PDAC, supported by RASolute 302 and prior breakthrough therapy and orphan drug designations. Phase 3 RASolute 302 showed OS nearly ...

FDA approval covers post–ROS1 inhibitor locally advanced/metastatic ROS1-positive NSCLC, granted ahead of the September 18, 2026 PDUFA date with breakthrough therapy and orphan drug designations.

ENDURANCE randomized 516 standard-risk, transplant-deferred patients after PI–lenalidomide induction to indefinite vs 2-year lenalidomide maintenance, powered for a 50% median OS improvement.

Betts, MD, discusses how discharging patients as early as day 5 after stem cell transplant has proved feasible and improves quality of life. Brian C. Betts, MD, Vice Chair of Strategic Initiatives for ...

FCA lymphodepletion produced dose-limiting toxicities, including grade 3 autoimmune hepatitis and fatal hyperinflammatory ...

Menin inhibitors like ziftomenib and revumenib target NPM1 and KMT2A AML, pushing precision therapy earlier with manageable toxicity. In an interview with Targeted Oncology, Eunice S. Wang, MD, of ...